Back to Search
Start Over
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia
- Publication Year :
- 2013
- Publisher :
- American Society of Hematology, 2013.
-
Abstract
- We evaluated long-term outcomes of 60 patients with chronic lymphocytic leukemia treated with an initial therapy of lenalidomide. At a median follow-up of 4 years, time-to-treatment failure has not been reached and overall survival is 82%. Thirty-five (58%) patients had a response lasting >36 months (long-term responders [LTRs]). Best LTR responses consisted of 25 (71%) complete remissions and 10 (29%) partial remissions. In addition to clinical responses, an increase in IgA, IgG, and IgM levels of >50% from baseline was reported in 61%, 45%, and 42% of LTRs. Normalization in the percentage of CD4+ and CD8+ cells and T-cell numbers was observed in 48%, 71% and 99% of LTRs. Compared with other patients in the study, LTRs had lower baseline plasma levels of β-2-microglobulin, were more likely to have trisomy 12, and less likely to have deletion 17p. This trial was registered at http://clinicaltrials.gov as # NCT00535873.
- Subjects :
- Long lasting
Immunoglobulin A
Male
medicine.medical_specialty
Neoplasm, Residual
Time Factors
Chronic lymphocytic leukemia
T-Lymphocytes
Immunology
Angiogenesis Inhibitors
Antineoplastic Agents
Biochemistry
Gastroenterology
Immunoglobulin G
Disease-Free Survival
Internal medicine
medicine
Humans
Lymphocyte Count
Lenalidomide
Aged
Aged, 80 and over
Lymphoid Neoplasia
biology
business.industry
fungi
Remission Induction
food and beverages
Cell Biology
Hematology
medicine.disease
Leukemia, Lymphocytic, Chronic, B-Cell
Thalidomide
biology.protein
Female
business
Trisomy
CD8
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....76c5b016c56fb2655c75bf8a4d3b8571